Anbio Biotechnology - Class A
Research Anbio Biotechnology - Class A (NNNN) on Bullrun: market cap USD 204.53M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerNNNN
- ExchangeNASDAQ
- CountryGermany
- SectorHealthcare
- IndustryMedical Instruments & Supplies
- CurrencyUSD
- Market capUSD 204.53M
- Financial periodFY2025
- RevenueUSD 8.65M
- Revenue growth5.6%
- Net incomeUSD 6.40M
- Free cash flow-USD 6.74M
- Gross margin87.2%
Valuation Snapshot
latest market cap is USD 204.53M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 8.65M | USD 6.40M | -USD 6.74M | 87.2% | 0.15 | USD 7.77M | n/a | USD 30.16M |
| FY2024 | USD 8.19M | USD 2.37M | USD 2.08M | 71.9% | 0.06 | USD 11.76M | n/a | USD 17.19M |
| FY2023 | USD 6.71M | USD 2.25M | USD 898.37K | 50.1% | 0.11 | USD 9.69M | n/a | USD 14.82M |
| FY2022 | USD 23.54M | USD 10.01M | USD 4.45M | 53.4% | 100112 | USD 7.10M | n/a | USD 12.55M |
| FY2021 | USD 4.43M | USD 2.54M | USD 4.18M | 57.4% | 0.03 | USD 4.18M | n/a | USD 2.54M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 204.53M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 1.32B | n/a | n/a | n/a |
About Anbio Biotechnology - Class A
Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, and internationally. The company offers lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, SHA dry chemistry, chemiluminescence immunoassay, and real-time polymerase chain reaction solutions; and SARS-CoV-2 and SARS-CoV-2/Flu A/Flu B antigen rapid test kits. It serves over-the-counter, point-of-care testing, and laboratory markets.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Anbio Biotechnology - Class A's market cap?
Anbio Biotechnology - Class A's market capitalization is USD 204.53M.
What does Anbio Biotechnology - Class A do?
Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, and internationally. The company offers lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, SHA dry chemistry, chemiluminescence immunoassay, and real-time polymerase chain reaction solutions; and SARS-CoV-2 and SARS-CoV-2/Flu A/Flu B antigen rapid test kits. It serves over-the-counter, point-of-care testing, and laboratory markets. Anbio Biotechnology was incorporated in 2021 and is based in Frankfurt am Main, Germany.